Concord Hospital, Neurosciences Department(2.0 mi away)Contact
+103 other location
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating
Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
Phase 3, multi-center, randomized withdrawal study to evaluate the sustained benefit in
efficacy and safety of ampreloxetine in subjects with primary autonomic failures (MSA, PD, or
PAF) and symptomatic nOH. The study consists of 3 periods: (i) 16-week open-label (OL)
treatment with ampreloxetine, (ii) 6-week randomized placebo-controlled treatment, and (iii)
2-week follow-up (only for patients who do not enroll in Study 0171 (long-term extension
Multiple System Atrophy,
Pure Autonomic Failure,
Symptomatic Neurogenic Orthostatic Hypotension,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.